JointHealth™ express February 2, 2017
Good news in British Columbia!
Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis listed by BC PharmaCare
As of January 31st, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on BC PharmaCare’s Limited Coverage Drug Program. Click here to view the detailed medication criteria.
Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.
To learn more about BC PharmaCare’s coverage of arthritis medications, click here.
Good news in British Columbia!
Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis listed by BC PharmaCare
As of January 31st, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on BC PharmaCare’s Limited Coverage Drug Program. Click here to view the detailed medication criteria.
Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.
To learn more about BC PharmaCare’s coverage of arthritis medications, click here.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.